The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
'Lack of diction is one of our least problems LOL. In fact diction went out the window some years ago, when Twitter fluttered in'
Sadly you are correct in part. However punctuation and correct use of the English language is now more a mark of the man than ever. Good grammar separates those who take the time to re-read their post and change them where required from those who just write what they think and post it without any thoughts as to the understandability of it.
At least Razor had the good grace to acknowledge his errors, he was probably tired.
Anyway, back to CEY. Indeed it was good to see the NE Chairman show support and I sold out of AVCT yesterday to add another tranche here. I'm sure the setback will be overcome and we will once again meet expectations. My only problem at the moment is how I split the considerable AVCT proceeds between CEY and SOLG, my other major goldie, with good news flowing daily on the run up to a possible offer from one of the majors. Nice problem to have.
MT:
I understand that as a DELT holder, you would wish to increase the value of your holding, but as most LTH's here will know, IOG's strategy is to acquire stranded or non-viable assets at knockdown prices and breath new life into them by the use of low cost, unmanned rigs, tied into our Bacton receiver, either with our own pipeline or others nearby.
Paying a premium for an unproven future asset, with all the future costs, would have been a risk and would not fit the original plan. We learned the possible pitfalls from Harvey!
Try studying the Relinquished Licenses posted on here earlier, and you will see that there is plenty of opportunity for IOG to consolidate and expand its operation without DELT or any unproven assets.
Well done the Board.
Although a merger would make sense at the right price, I'm relieved that we didn't pay the silly prices being bandied about.
Let's face it, DELT have a good asset, possibly, but they are so far off even validating the figures, let alone producing anything, that they will need a lot of financial support from the shareholders or possibly a kind 'Uncle', (Shell?) to reach any real value.
Probably a good buy at .85p for those with a lot of patience.
A good point, well made.
Had the company done nothing, the result could have been catastrophic and the SP would have been a lot lower.
Better by far to take control of the situation and protect the workforce and the future of the company.
Hi Rebess,
You're not alone in finding CEY a frustrating share, but hasn't it always been the case?
When I first bought in 2017. I was looking for a good dividend, which CEY did provide. That caused me to hold and watch the price yo-yo as it did in those days, until I started to trade the share last year or so. I've been lucky with the price fluctuations and have been patient waiting for the tips and dips.
I sold out completely at 220p and have got back in at 159p today. I missed the dividend, but waited for a significant event (like today) in order to get back in.
I will wait and hold, but will sell out again should the opportunity arise. I'm not convinced the West African assets are that good, but understand the rationale behind the move. In the meantime, I'll (hopefully) get a reasonable income and enjoy the ride.
...it is a perfect opportunity to re-join the CEY club.
I originally bought at 92p and sold out at 220p, but always felt bad about it for some reason.
Sadly for those who held on, I feel a retrace will happen, but this will enable me to buy back my original holding, and more, for the same amount.
Good luck all.
'Someone put on Twitter'...
Must be true then!
Idiot.
...a bit odd. Flat for quite while and all morning and then rose quite quickly from 1:30pm ish. Which is when the NYSE are in their pre trading period. I wonder if we can expect an RNS regarding the US operations or perhaps an update on the Harwell Vaccine Centre in line with the Governments latest push.
Certainly something stirred the embers!
...to me that if the Affirmers work as SKIN suggest, there will be others developing 'Breathalyser' tests which will need Avacta's product. The potential market is limited only by the ability to produce.
Good news for the all.